"Angesichts des Coronavirus ist das Hanusch-Krankenhaus nur für dringend nötige medizinische Behandlungen und Notfälle geöffnet. Der Eingang erfolgt nur über den Pavillon 4 (Rettungszufahrt). Hier gibt es eine Zugangskontrolle (Fiebermessen und Kurzbefragung). Die Versorgung von Notfällen erfolgt nach der Zugangskontrolle in der neuen Zentralen Erstaufnahme Einheit. Patientinnen und Patienten, die als potentiell Covid-19 infiziert gelten und nicht als Notfall kategorisiert werden, werden an 1450 verwiesen. Im ganzen Haus ist Besuchsverbot! Falls Sie Fieber oder Husten haben und Kontakt zu einem Corona-Verdachtsfall hatten bzw. zuletzt in einem Risikogebiet waren, rufen Sie die Gesundheitsberatung 1450 oder den Ärztenotdienst 141."

During the past decade, Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung" #1 collaborator was "Assign Data Management and Biostatistics GmbH" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Medical University of Vienna" with 1 trials as a collaborator, "Sanofi" with 1 trials as a collaborator and "University of Navarra" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung" are "Multiple Myeloma" (1 trials) and "Newly Diagnosed Multiple Myeloma" (1 trials). Many other conditions were trialed in "Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung" in a lesser frequency.

Most popular intervention types in "Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]" (1 trials), "Dexamethasone Oral" (1 trials), "Isatuximab-Irfc 20 MG/ML [Sarclisa]" (1 trials), "Lenalidomide" (1 trials) and "Placebo 1.7 ml Subcutaneous Solution" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hanusch Krankenhaus der Österreichischen Gesundheitskasse, 3. Med. Abteilung, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".